Certest Pharma specializes in the development of advanced lipid nanoparticle (LNP) technologies, with a strong focus on enabling efficient and targeted delivery of next-generation RNA-based therapies. At the core of its platform is a pioneering library of proprietary ionizable lipids, designed to optimize delivery performance and therapeutic outcomes.

The company offers its technology through licensing opportunities, covering comprehensive solutions that include the design and development of high-performing ionizable lipids, optimized LNP formulations, and robust RNA sequences. In addition, Certest Pharma has extensive expertise in the design, production, and analysis of oligonucleotides under GMP-like quality standards.

Its capabilities span a wide range of RNA applications, from short sequences to complex, large-scale constructs. By integrating innovation and cutting-edge technology, Certest Pharma positions itself as a leading provider of lipid-based delivery solutions. The company actively collaborates with pharmaceutical companies, academic institutions, and research partners worldwide to advance scientific progress and improve global healthcare outcomes.